Hikma Pharmaceuticals PLC 2017 AR2
The report highlights Hikma Pharmaceuticals' performance and sustainability initiatives for the fiscal year 2017. Despite facing significant headwinds in its US Generics business, the company delivered a solid performance in its Branded and Injectables segments, achieving a Group revenue of $1,936 million. Key sustainability achievements included maintaining its position in the FTSE4Good index, donating over 340,000 units of medicine, and completing a wastewater treatment facility in Egypt. Additionally, the company took steps to address modern slavery in its supply chain and promoted patient safety by distributing 500,000 smart syringes in Jordan.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2017
Type: AR2
Pages: 184
Back to company
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma Pharmaceuticals' performance and sustainability initiatives for the fiscal year 2017. Despite facing significant headwinds in its US Generics business, the company delivered a solid performance in its Branded and Injectables segments, achieving a Group revenue of $1,936 million. Key sustainability achievements included maintaining its position in the FTSE4Good index, donating over 340,000 units of medicine, and completing a wastewater treatment facility in Egypt. Additionally, the company took steps to address modern slavery in its supply chain and promoted patient safety by distributing 500,000 smart syringes in Jordan.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Employees